[ccpw id="5"]

Home.forex news reportMorgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to...

Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating

-


IQVIA Holdings Inc. (NYSE:IQV) is among the 10 Best Consensus Buy-Rated Stocks to Invest in. On February 11, 2026, Morgan Stanley lowered its price target on IQVIA Holdings Inc. (NYSE:IQV) to $240 from $265 but still maintained an Overweight rating, updating its estimates after the company’s quarterly results.

On February 10, 2026, IQVIA Holdings Inc. (NYSE:IQV) and the Duke Clinical Research Institute announced a collaboration aimed at advancing clinical research in obesity and related cardiometabolic trials. Chief Medical and Scientific Officer Jeffrey Spaeder said the partnership is designed to “set a new standard for prospective collaboration” between life science service companies and academic research organizations, with a focus on accelerating clinical trial planning and delivery. The companies said the combined capabilities are intended to improve trial efficiency and speed timelines for bringing therapies to patients.

IQVIA reported fourth-quarter revenue of $4.36 billion on February 5, 2026, above the $4.08 billion consensus estimate. CEO Ari Bousbib said the company closed 2025 with strong performance across all segments, delivering near double-digit revenue and EPS growth, along with its strongest quarter of the year in R&DS net bookings. He added that expanded go-to-market efforts, operational discipline, and AI-related investments supported topline growth across both commercial and clinical businesses, positioning the company for 2026.

Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating
Morgan Stanley Lowers its Price Target on IQVIA Holdings Inc. (IQV) to $240 but Maintains an Overweight Rating

Copyright: dolgachov / 123RF Stock Photo

IQVIA Holdings Inc. (NYSE:IQV) provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.

While we acknowledge the potential of IQV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

LATEST POSTS

Chart Art: USD/CHF Triangle Support Near .7700

The U.S. dollar’s latest pullback has traders zeroing in on a key support zone on USD/CHF. Will buyers step in and defend this area, or...

JPMorgan Raises its Price Target on Vistra Corp. (VST) to $239 and Maintains an Overweight Rating

Vistra Corp. (NYSE:VST) is among the 10 Best Consensus Buy-Rated Stocks to Invest in. On February 12, 2026, JPMorgan analyst Jeremy...

Citi Raises its Price Target on HubSpot (HUBS) to $640 and Maintains a Buy Rating

HubSpot, Inc. (NYSE:HUBS) is among the 10 Best Consensus Buy-Rated Stocks to Invest in. On February 13, 2026, Citi raised its...

Corning (GLW) Hits All-Time High as Analyst Hikes PT by 28%

We recently published 10 Stocks Outrunning the Market; 3 on a High. Corning Inc. (NYSE:GLW) was one of the best performers...

Follow us

0FansLike
0FollowersFollow
0SubscribersSubscribe

Most Popular

spot_img